Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 27-32

  Oiso, Shigeru ^a   Ikeda, Ryuji ^b   Nakamura, Kazuo ^c   Takeda, Yasuo ^b   Akiyama, Shin Ichi ^d   Kariyazono, Hiroko ^a  

^a NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cisplatin; Curcumin; Human epidermoid carcinoma; NF B

Indexed keywords

CISPLATIN; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL NUCLEUS; CELL STRAIN KB 3 1; CELL STRAIN KCP 4; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SQUAMOUS CELL CARCINOMA;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CISPLATIN; CURCUMIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84861554715     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1801     Document Type: Article

References (36)

1. Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med 100: 704-713, 1984.
2. Comess KM, Burstyn JN, Essigmann JM and Lippard SJ: Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum (II) DNA adducts. Biochemistry 31: 3975-3990, 1992.
3. Corda Y, Anin MF, Leng M and Job D: RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II). Biochemistry 31: 1904-1908, 1992.
4. Heminger KA, Hartson SD, Rogers J and Matts RL: Cisplatin inhibits protein synthesis in rabbit reticulocyte lysate by causing an arrest in elongation. Arch Biochem Biophys 344: 200-207, 1997. (Pubitemid 27328113)
5. Jordan P and Carmo-Fonseca M: Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res 26: 2831-2836, 1998. (Pubitemid 28297513)
6. Rosenberg JM and Sato PH: Cisplatin inhibits in vitro translation by preventing the formation of complete initiation complex. Mol Pharmacol 43: 491-497, 1993. (Pubitemid 23082008)
7. Suo Z, Lippard SJ and Johnson KA: Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry 38: 715-726, 1999.
8. Wang G, Reed E and Li QQ: Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 12: 955-965, 2004.
9. Kelland LR: New platinum antitumor complexes. Crit Rev Oncol Hematol 15: 191-219, 1993.
10. Timmer-Bosscha H, Mulder NH and de Vries EG: Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 66: 227-238, 1992.
11. Timmer-Bosscha H, Mulder NH and de Vries EG: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
12. Beale PJ, Rogers P, Boxall F, Sharp SY and Kelland LR: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 82: 436-440, 2000. (Pubitemid 30045394)
13. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112: 974-985, 2004. (Pubitemid 39507003)
14. Kim JK, Kim KD, Lee E, Lim JS, Cho HJ, Yoon HK, Cho MY, Baek KE, Park YP, Paik SG, et al: Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 212: 61-70, 2004. (Pubitemid 38887721)
15. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, and Clarke R: BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 24: 2040-2055, 2010.
16. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R and Franzoso G: Induction of gadd45β by NF-κB down-regulates pro-apoptotic JNK signalling. Nature 414: 308-313, 2001. (Pubitemid 33097807)
17. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M and Anning Lin: Inhibition of JNK activation through NF-κB target genes. Nature 414: 313-317, 2001.
18. Baud V and Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40, 2009.
19. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, et al: Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485, 2004. (Pubitemid 38685659)
20. Venkatraman M, Anto RJ, Nair A, Varghese M and Karunagaran D: Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44: 51-59, 2005. (Pubitemid 41216407)
21. Wilken R, Veena MS, Wang MB and Srivatsan ES: Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10: 12-31, 2011.
22. Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 270: 24995-25000, 1995.
23. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S and Aggarwal BB: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8: 959-970, 2009.
24. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y and Nimmannit U: Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest 27: 624-635, 2009.
25. Dhandapani KM, Mahesh VB and Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102: 522-538, 2007. (Pubitemid 47000605)
26. Fujii R, Mutoh M, Sumizawa T, Chen ZS, Yoshimura A and Akiyama S: Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J Natl Cancer Inst 86: 1781-1784, 1994. (Pubitemid 24373454)
27. Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, Kuwano M and Akiyama S: Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85: 426-433, 1994. (Pubitemid 24129624)
28. Chen ZS, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, Saijo N, Kondo T and Akiyama S: An active efflux system for heavy metals in cisplatin-resistant human KB, carcinoma cells. Exp Cell Res 240: 312-320, 1998. (Pubitemid 28371112)
29. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
30. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
31. Eichholtz-Wirth H and Sagan D: IkappaB/NF-kappaB mediated cisplatin resistance in HeLa cells after low-dose gamma-irradiation is associated with altered SODD expression. Apoptosis 5: 255-263, 2000.
32. Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949, 2004. (Pubitemid 38638854)
33. Reuter S, Eifes S, Dicato M, Aggarwal BB and Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76: 1340-1351, 2008.
34. Chan MM, Fong D, Soprano KJ, Holmes WF and Heverling H: Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194: 63-70, 2003. (Pubitemid 35424228)
35. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, Faull KF, Srivatsan ES and Wang MB: Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther 9: 2665-2675, 2010.
36. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES and Wang MB: Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 14: 6228-6236, 2008.